Long-term successful adalimumab therapy in severe hidradenitis suppurativa

Archives of Dermatology

Volumn 145, Issue 5, 2009, Pages 580-584

  Blanco, Ricardo ^a   Martínez Taboada, Víctor M ^a   Villa, Ignacio ^a   González Vela, M Carmen ^a   Fernández Llaca, Héctor ^a   Agudo, Mario ^a   González López, Marcos A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; CEFTRIAXONE; ETANERCEPT; ISOTRETINOIN; ORAL CONTRACEPTIVE AGENT; PREDNISONE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CELLULITIS; CLINICAL ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE DURATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE PAIN; LONG TERM CARE; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SKIN FISTULA; SKIN NODULE; SUPPURATIVE HIDRADENITIS; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HIDRADENITIS SUPPURATIVA; HUMANS; INJECTIONS, SUBCUTANEOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 66149105427     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.49     Document Type: Article

References (25)

1. Kurzen H, Kurokawa I, Jemec GBE, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17(5):455-472.
2. Wiseman MC. Hidradenitis suppurativa: a review. Dermatol Ther. 2004;17(1):50-54.
3. Sellheyer K, Krahl D. "Hidradenitis suppurativa" is acne inversa: an appeal to (finally) abandon a misnomer. Int J Dermatol. 2005;44(7):535-540. (Pubitemid 40965409)
4. Jansen I, Altmeyer P, Piewig G. Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol. 2001;15(6):532-540. (Pubitemid 34044089)
5. von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809-813. (Pubitemid 32374785)
6. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J; Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621-623.
7. Jackson JM. TNF-α inhibitors. Dermatol Ther. 2007;20(4):251-264.
8. Graves JE, Nunley J, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56(1):e55-e79. doi:10.1016/j.jaad.2006.07.019.
9. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56(4):624-628. (Pubitemid 46400174)
10. Usmani N, Clayton TH, Everett S, Goodfield J. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32(2):204-205. (Pubitemid 46233031)
11. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154(4):726-729. (Pubitemid 43374099)
12. Moul DK, Korman NJ. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006;142(9):1110-1112. (Pubitemid 44414393)
13. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J Am Acad Dermatol. 2006;55(1):163-164. (Pubitemid 43867032)
14. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol. 1997;136(3):305-314. (Pubitemid 27105848)
15. De Tiedra AG, Mercadal J, Badía X, Mascaro JM, Herdmann M, Lozano R. Spanish transcultural adaptation of the questionnaire Dermatology Life Quality Index (DLQI): Indice de Calidad de Vida en Dermatología. Actas Dermosifiliogr. 1998;98(12):692-700.
16. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139(12):1540-1542. (Pubitemid 37523071)
17. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149(5):1046-1049. (Pubitemid 37541993)
18. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat. 2005;16(1):58-61. (Pubitemid 40283328)
19. Roussomoustakaki M, Dimoulios P, Chatzicostas C, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol. 2003;38(10):1000-1004. (Pubitemid 37455790)
20. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol. 2002;97(8):2155-2156.
21. Martínez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis. 2001;7(4):323-326.
22. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158(2):370-374.
23. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158(3):567-572.
24. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368-2376. (Pubitemid 44204996)
25. Russ E, Castillo M. Lumbosacral epidural abscess due to hidradenitis suppurativa. AJR Am J Roentgenol. 2002;178(3):770-771. (Pubitemid 34178175)